Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC

NCT07224841 · clinicaltrials.gov ↗

RECRUITING

Status

500

Enrollment

OTHER

Sponsor class

Conditions

CRC (Colorectal Cancer)

Interventions

DIAGNOSTIC_TEST: cfDNA 5mC/5hmC Sequencing (EpiDRIVE Discovery Phase)
DIAGNOSTIC_TEST: EpiDRIVE Assay (Targeted Sequencing / qPCR Validation)

Sponsor

City of Hope Medical Center